Osorio SC, Nápoles ALL, Vallés GAS, Caballero LA

Language: Spanish
References: 15
Page: 144-150
PDF size: 315.74 Kb.

ABSTRACT

Background: insulin resistance and associated metabolic alterations, such as dyslipidemia, hypertension, obesity and hypercoagulability, influence the increasingly premature appearance and severity of atherosclerosis that patients with diabetes mellitus develop.
Objective: to evaluate the biochemical markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus.
Method: a descriptive and cross-sectional study was carried out to evaluate biochemical markers of subclinical atherosclerosis in 100 patients with type 2 diabetes mellitus treated at the Guillermo Dominguez López General Teaching Hospital from April 2020 to March 2021. The used variables were: age, sex, blood pressure, personal medical history of diabetes mellitus, toxic habits and cardiovascular risk. These patients were classified according to their global cardiovascular risk using the risk charts established by the World Health Organization for the Americas region and total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, creatinine, uric acid determinations were performed, cystatin C, fibrinogen, high-sensitivity C-reactive protein. The information was processed using descriptive statistics methods, mainly rates and percentages.
Results: most of the patients were classified in global cardiovascular risk 2 and 3. Their markers showed association with the risk categories established in each patient. The determinations of triglycerides, HDL-cholesterol and uric acid were the most significant to identify vascular damage in patients with type 2 diabetes mellitus.
Conclusions: there was a direct relationship between altered values ​​of high-sensitivity C-reactive protein and global cardiovascular risk in the studied patients.

REFERENCES

1. Valdés A, Naranjo A. Enfermedad aterosclerótica subclínica. Rev Cubana Car Cir Cardiovas[Internet]. 2019[citado 7 Dic 2021];25(4):[aprox. 10p.]. Disponible en: https://revcardiologia.sld.cu/index.php/revcardiologia/article/view/9061.

2. Martínez W, Rivera A, Chávez M. Factores involucrados en la enfermedad cardiovascular aterosclerótica y su potencial utilidad como biomarcadores. Rev Méd Rosario[Internet]. 2020[citado 7 Dic 2021];86(3):[aprox. 12p.]. Disponible en: https://revistamedicaderosario.org/index.php/rm/article/view/114/1622.

3. Moreyra E, Lorenzatti D, Moreyra C, Arias V, Tibaldi MA, Lepori AJ, et al. Comparison of risk scores to predict subclinical atherosclerosis. Medicina (B Aires). 2019;79(5):373-83.

4. Herrera A, González D, Tamargo T, Soto J, Peña Y. Factores pronósticos de aterosclerosis subclínica en pacientes dislipidémicos. Rev Cubana Med[Internet]. 2020[citado 7 Dic 2021];59(4):[aprox. 8p.]. Disponible en: https://revmedicina.sld.cu/index.php/med/article/view/16634.

5. Licea M. Aterosclerosis y diabetes mellitus: revisión bibliográfica. Rev Cubana Med[Internet]. 1986[citado 4 Ene 2022];25(12):[aprox. 28p.]. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/lil-519235.

6. Gajardo L, Lecannelier E, Venegas R, Pérez L, Saldaña Á, Vargas G, et al. Diferencias en la aterosclerosis coronaria entre hombres y mujeres con diabetes mellitus tipo 2 evaluados con el Score de Gensini. Rev Chil Cardiol[Internet]. 2012[citado 7 Dic 2021];31(2):[aprox. 5p.]. Disponible en: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-85602012000200002&lng=es6.

7. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl. 1):S13-S28.

8. Valdés ER, Valdés ER, Valdés NN. Factores de riesgo asociados a las complicaciones cardiovasculares en mujeres de edad mediana con diabetes mellitus tipo 2. Rev Cubana Endocrinol[Internet]. 2020[citado 7 Dic 2021];31(2):[aprox. 7p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532020000200006&lng=es378.

9. De Ritter R, Sep SJ, van der Kallen CJ, Schram MT, Koster A, Kroon AA, et al. Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht Study. BMJ Open Diabetes Res Care. 2019;7(1):e000787.

10. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer SG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. Arch Intern Med. 2001;161(14):1717-23.

11. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulación. 2003;107(3):499-511.

12. Pérez P, Abellán J, Jurado A, Sánchez I, López MT, Frías R, et al. Biomarcadores inflamatorios y extensión de aterosclerosis coronaria en pacientes con síndrome coronario agudo: Estudio observacional prospectivo en un hospital general universitario. Rev Colomb Cardiol[Internet]. 2020[citado 7 Dic 2021];27(6):[aprox. 6p.]. Disponible en: https://www.elsevier.es/es-revista-revista-colombiana-cardiologia-203-pdf-S012056332030049812.

13. Elosua R, Morales A. Determinación del riesgo cardiovascular total. Caracterización, modelización y objetivos de la prevención según el contexto sociodemográfico. Rev Esp Cardiol[Internet]. 2016[citado 7 Dic 2021];11(Suppl. E):[aprox. 10p.]. Disponible en: https://www.revespcardiol.org/es-pdf-S113135871115002513.

14. Manzur F, Alvear C, Alayón AN. Papel de la proteína c reactiva en las enfermedades cardiovasculares. Rev Colomb Cardiol[Internet]. 2011[citado 7 Dic 2021];18(5):[aprox. 5p.]. Disponible en: https://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-56332011000500006&lng=es14.

15. Levenson P, Giral M, Razavian J, Gariepy A, Sinom A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995;15(9):1263-8.